JP2017532289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532289A5 JP2017532289A5 JP2017500952A JP2017500952A JP2017532289A5 JP 2017532289 A5 JP2017532289 A5 JP 2017532289A5 JP 2017500952 A JP2017500952 A JP 2017500952A JP 2017500952 A JP2017500952 A JP 2017500952A JP 2017532289 A5 JP2017532289 A5 JP 2017532289A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- amino acid
- proline
- tryptophan
- phenylalanine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims 50
- 229940024606 amino acid Drugs 0.000 claims 31
- 235000001014 amino acid Nutrition 0.000 claims 31
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 28
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 28
- 235000013930 proline Nutrition 0.000 claims 28
- 229960002429 proline Drugs 0.000 claims 28
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 24
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 24
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 24
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 24
- 235000008729 phenylalanine Nutrition 0.000 claims 24
- 229960005190 phenylalanine Drugs 0.000 claims 24
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 24
- 229960004799 tryptophan Drugs 0.000 claims 24
- 235000002374 tyrosine Nutrition 0.000 claims 24
- 229960004441 tyrosine Drugs 0.000 claims 24
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 24
- 239000004475 Arginine Substances 0.000 claims 22
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 22
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 22
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 22
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 22
- 239000004472 Lysine Substances 0.000 claims 22
- 235000009697 arginine Nutrition 0.000 claims 22
- 229960003121 arginine Drugs 0.000 claims 22
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 22
- 235000014304 histidine Nutrition 0.000 claims 22
- 229960002885 histidine Drugs 0.000 claims 22
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 22
- 235000018977 lysine Nutrition 0.000 claims 22
- 229960003646 lysine Drugs 0.000 claims 22
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 21
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 21
- 235000003704 aspartic acid Nutrition 0.000 claims 21
- 229960005261 aspartic acid Drugs 0.000 claims 21
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 21
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 20
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 20
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 20
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 20
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 20
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 20
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 20
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 20
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 20
- 239000004473 Threonine Substances 0.000 claims 20
- 235000009582 asparagine Nutrition 0.000 claims 20
- 229960001230 asparagine Drugs 0.000 claims 20
- 235000018417 cysteine Nutrition 0.000 claims 20
- 229960002433 cysteine Drugs 0.000 claims 20
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 20
- 235000013922 glutamic acid Nutrition 0.000 claims 20
- 229960002989 glutamic acid Drugs 0.000 claims 20
- 239000004220 glutamic acid Substances 0.000 claims 20
- 235000004400 serine Nutrition 0.000 claims 20
- 229960001153 serine Drugs 0.000 claims 20
- 235000008521 threonine Nutrition 0.000 claims 20
- 229960002898 threonine Drugs 0.000 claims 20
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 18
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 18
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 18
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 18
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 18
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 18
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 18
- 235000004554 glutamine Nutrition 0.000 claims 18
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 18
- 229960002743 glutamine Drugs 0.000 claims 18
- 235000014705 isoleucine Nutrition 0.000 claims 18
- 229960000310 isoleucine Drugs 0.000 claims 18
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 18
- 235000005772 leucine Nutrition 0.000 claims 18
- 229960003136 leucine Drugs 0.000 claims 18
- 235000006109 methionine Nutrition 0.000 claims 18
- 229930182817 methionine Natural products 0.000 claims 18
- 229960004452 methionine Drugs 0.000 claims 18
- 235000014393 valine Nutrition 0.000 claims 18
- 229960004295 valine Drugs 0.000 claims 18
- 239000004474 valine Substances 0.000 claims 18
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 11
- 235000004279 alanine Nutrition 0.000 claims 11
- 229960003767 alanine Drugs 0.000 claims 11
- 239000004471 Glycine Substances 0.000 claims 10
- 229960002449 glycine Drugs 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 102000004211 Platelet factor 4 Human genes 0.000 claims 8
- 108090000778 Platelet factor 4 Proteins 0.000 claims 8
- 206010002022 amyloidosis Diseases 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 230000009260 cross reactivity Effects 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 3
- 210000004408 hybridoma Anatomy 0.000 claims 3
- -1 L 34 Chemical compound 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims 1
- 229940049906 glutamate Drugs 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462021308P | 2014-07-07 | 2014-07-07 | |
| US62/021,308 | 2014-07-07 | ||
| PCT/EP2015/065362 WO2016005328A2 (en) | 2014-07-07 | 2015-07-06 | IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020156999A Division JP2021001203A (ja) | 2014-07-07 | 2020-09-18 | 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017532289A JP2017532289A (ja) | 2017-11-02 |
| JP2017532289A5 true JP2017532289A5 (enExample) | 2018-08-16 |
Family
ID=53525183
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017500952A Pending JP2017532289A (ja) | 2014-07-07 | 2015-07-06 | 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用 |
| JP2020156999A Pending JP2021001203A (ja) | 2014-07-07 | 2020-09-18 | 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用 |
| JP2022192713A Pending JP2023036606A (ja) | 2014-07-07 | 2022-12-01 | 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020156999A Pending JP2021001203A (ja) | 2014-07-07 | 2020-09-18 | 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用 |
| JP2022192713A Pending JP2023036606A (ja) | 2014-07-07 | 2022-12-01 | 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20160000891A1 (enExample) |
| EP (1) | EP3166969A2 (enExample) |
| JP (3) | JP2017532289A (enExample) |
| CN (1) | CN107074924A (enExample) |
| AU (2) | AU2015286824A1 (enExample) |
| CA (1) | CA2954031A1 (enExample) |
| IL (1) | IL249925B (enExample) |
| MX (1) | MX2017000094A (enExample) |
| RU (1) | RU2750268C2 (enExample) |
| SG (1) | SG11201700071WA (enExample) |
| WO (1) | WO2016005328A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201706600VA (en) | 2005-11-30 | 2017-09-28 | Abbvie Inc | Monoclonal antibodies and uses thereof |
| EP2558494B1 (en) * | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta binding proteins |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| RU2750268C2 (ru) * | 2014-07-07 | 2021-06-25 | Эббви Дойчланд Гмбх Унд Ко. Кг | ИММУНОГЕННЫЕ ПРОДУКТЫ, ПОЛУЧЕННЫЕ НА ОСНОВЕ АМИНОКИСЛОТНЫХ ПОСЛЕДОВАТЕЛЬНОСТЕЙ МУТЕИНОВОГО АМИЛОИДА β (Aβ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| CN109477832A (zh) | 2016-09-06 | 2019-03-15 | 富士瑞必欧株式会社 | 甲状腺球蛋白的测定方法及测定试剂 |
| JP6999561B2 (ja) * | 2016-09-13 | 2022-02-10 | 富士レビオ株式会社 | 心筋トロポニンの測定方法及び測定試薬 |
| IL280880B2 (en) | 2018-08-27 | 2025-04-01 | Regeneron Pharma | Using Raman Spectroscopy in Downstream Purification |
| CN110412294B9 (zh) * | 2019-08-07 | 2023-05-26 | 深圳市新产业生物医学工程股份有限公司 | 蛋白稳定液、蛋白校准品、试剂盒及检测蛋白校准品稳定性的方法 |
| US12352719B2 (en) | 2019-09-20 | 2025-07-08 | KYCERA AVX Components Corporation | Somatic cell-based electrical biosensor |
| CN112851786B (zh) * | 2019-11-12 | 2022-11-15 | 深圳市新产业生物医学工程股份有限公司 | 可溶性的Aβ1-42变体、Aβ1-42校准品及试剂盒 |
| CN111793131A (zh) * | 2020-05-11 | 2020-10-20 | 廊坊天光生物技术有限公司 | 一种用于检测血清中pf4含量的抗体对及其用途 |
| KR102711715B1 (ko) * | 2021-01-28 | 2024-09-30 | 주식회사 에이브레인 | 신경 퇴행성 질환의 치료를 위한 유전자 요법 |
| EP4230645A1 (en) * | 2022-02-22 | 2023-08-23 | Technische Universität München | Peptidic inhibitors of amyloid self- and cross-assembly |
| CN117700525B (zh) * | 2024-02-05 | 2024-06-18 | 上海良润生物医药科技有限公司 | 一种多肽改造体及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| KR20080090408A (ko) * | 2005-11-30 | 2008-10-08 | 아보트 러보러터리즈 | 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법 |
| US20110092445A1 (en) * | 2008-07-25 | 2011-04-21 | Abbott Laboratories | Amyloid ß peptide analogues, oligomers thereof, processes for preparing and composi-tions comprising said analogues or oligomers, and their uses |
| EP2558494B1 (en) * | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta binding proteins |
| US9062101B2 (en) * | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| RU2750268C2 (ru) * | 2014-07-07 | 2021-06-25 | Эббви Дойчланд Гмбх Унд Ко. Кг | ИММУНОГЕННЫЕ ПРОДУКТЫ, ПОЛУЧЕННЫЕ НА ОСНОВЕ АМИНОКИСЛОТНЫХ ПОСЛЕДОВАТЕЛЬНОСТЕЙ МУТЕИНОВОГО АМИЛОИДА β (Aβ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
-
2015
- 2015-07-06 RU RU2017103527A patent/RU2750268C2/ru active
- 2015-07-06 JP JP2017500952A patent/JP2017532289A/ja active Pending
- 2015-07-06 WO PCT/EP2015/065362 patent/WO2016005328A2/en not_active Ceased
- 2015-07-06 CN CN201580047718.9A patent/CN107074924A/zh active Pending
- 2015-07-06 CA CA2954031A patent/CA2954031A1/en active Pending
- 2015-07-06 SG SG11201700071WA patent/SG11201700071WA/en unknown
- 2015-07-06 AU AU2015286824A patent/AU2015286824A1/en not_active Abandoned
- 2015-07-06 EP EP15735674.2A patent/EP3166969A2/en not_active Withdrawn
- 2015-07-06 MX MX2017000094A patent/MX2017000094A/es unknown
- 2015-07-06 US US14/792,500 patent/US20160000891A1/en not_active Abandoned
-
2017
- 2017-01-04 IL IL249925A patent/IL249925B/en unknown
-
2020
- 2020-09-18 JP JP2020156999A patent/JP2021001203A/ja active Pending
-
2021
- 2021-01-29 AU AU2021200575A patent/AU2021200575A1/en not_active Abandoned
-
2022
- 2022-10-27 US US18/050,314 patent/US20240075114A1/en active Pending
- 2022-12-01 JP JP2022192713A patent/JP2023036606A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017532289A5 (enExample) | ||
| RU2017103527A (ru) | ИММУНОГЕННЫЕ ПРОДУКТЫ, ПОЛУЧЕННЫЕ НА ОСНОВЕ АМИНОКИСЛОТНЫХ ПОСЛЕДОВАТЕЛЬНОСТЕЙ МУТЕИНОВОГО АМИЛОИДА β(Aβ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2011529084A5 (enExample) | ||
| JP2020537520A5 (enExample) | ||
| JPH06501938A (ja) | ペプチドよりなるｈｉｖ複製阻害剤 | |
| JP2011528561A5 (enExample) | ||
| JP2011523550A5 (enExample) | ||
| RU2013129815A (ru) | Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул | |
| Yamada et al. | Ile‐Lys‐Val‐Ala‐Val (IKVAV)‐containing laminin α1 chain peptides form amyloid‐like fibrils | |
| JP2020524675A5 (enExample) | ||
| RU2008120027A (ru) | Анти-addl моноклональное антитело и его применение | |
| RU2011100125A (ru) | Соединения для лечения амилоидозов | |
| JP2019502684A5 (enExample) | ||
| RU2015126533A (ru) | Анти-cd47 антитела и способы их применения | |
| WO2005025616A1 (ja) | 抗体の用途 | |
| FI2897981T3 (fi) | Anti-CD3-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat CD3:a ja CD20:ta, ja niiden käyttöjä | |
| RU2012140954A (ru) | Антитела, связывающиеся с протофибриллами, и их применение в методах терапии и диагностики болезни паркинсона, деменции, ассоциированной с образованием диффузных телец леви, и других а-синуклеинопатий | |
| RU2010151725A (ru) | Аминокислотные последовательности, направленные против cхcr4 и других gpcr, и соединения, включаюшие их | |
| RU2014102007A (ru) | Методы предсказания, обнаружения и уменьшения неспецифической интерференции белков в способах анализа с использованием одиночных вариабельных доменов иммуноглобулинов | |
| CA2501945A1 (en) | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof | |
| RU2008126241A (ru) | Моноклональные антитела и их применения | |
| EA200970694A1 (ru) | ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ | |
| JP2009519895A5 (enExample) | ||
| RU2013106270A (ru) | Моноклональное антитело против addl и его применения | |
| JP2013524774A5 (enExample) |